Human Immunodeficiency Virus Clinical Trial
Official title:
An Open-label Phase III Study to Investigate the Safety, Tolerability and Immunogenicity of a Nine-valent Human Papillomavirus (HPV) Vaccine (Gardasil®9) in Solid Organ Transplant Recipients and HIV-infected Patients
This is a single-center, open-label study on safety, tolerability and immunogenicity of
Gardasil®9 in 18 to 45 year-old HIV patients, in 18 to 55 year-old solid-organ transplant
(SOT) patients.
This study will enrol 100 HIV patients with CD4+ count of >200cells/mm² and 170 SOT patients,
all of whom have not yet received a prophylactic HPV vaccine. The 170 SOT patients will be
equally divided over 3 different SOT patient groups, namely heart, lung and kidney transplant
patients. Therefore the target is to include approximately 57 heart transplant patients, 57
lung transplant patients and 57 kidney transplant patients. Enrolment in a SOT subgroup will
be stopped when 57 patients have been included unless recruitment cannot be achieved within
one of the other SOT-patient population.
All enrolled subjects will receive a 3-dose regimen (Day 1, Month 2, and Month 6) of
GARDASIL®9. Serum samples will be collected on Day 1 and Month 7 for anti-HPV 6, 11, 16, 18,
31, 33, 45, 52, and 58 antibody determination. The time point for comparison of immune
responses will be Month 7, or approximately 4 weeks after the administration of the third
dose. The safety/tolerability profile of the vaccine will be evaluated in all subjects in the
study. Safety information will be collected on Day 1 through 1 month following the third
vaccination or for a total of approximately 7 months for each subject.
The immunogenicity and the safety data will be analyzed per group of patients. More
specifically a separate analysis of HIV and SOT patients is planned, since it is expected
that the immunosuppressive therapy of SOT patients might have a more profound effect on
immunogenicity following vaccination.
This study will provide a comparison of immunogenicity of Gardasil ®9 in immunocompromised
patients, with historical controls. The number of subjects to be enrolled in the study was
determined based on the primary immunogenicity objective.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03516318 -
Using Social Media to Improve ART Retention and Treatment Outcomes Among YLHIV in Nigeria
|
N/A | |
Completed |
NCT04653194 -
Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'
|
Phase 3 | |
Completed |
NCT01792570 -
DRV/r + RPV QD: Efficacy and Toxicity Reduction
|
Phase 3 | |
Active, not recruiting |
NCT04826562 -
Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)
|
Phase 4 | |
Completed |
NCT04191967 -
Thermocoagulation for Treatment of Precancerous Cervical Lesions
|
N/A | |
Completed |
NCT02812329 -
Intervention to Encourage HIV Testing and Counseling Among Adolescents
|
Phase 1 | |
Completed |
NCT02919306 -
Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults
|
Phase 1/Phase 2 | |
Completed |
NCT02516930 -
A Non-inferiority Randomized Controlled Trial to Evaluate Promoting Condom Use Among MSM and Transgender Individuals in China
|
N/A | |
Completed |
NCT02651376 -
Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT02392884 -
HIV Medication Adherence in Underserved Populations
|
N/A | |
Completed |
NCT01944371 -
Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT01778374 -
Mater-Bronx Rapid HIV Testing Project.
|
N/A | |
Completed |
NCT00914225 -
Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya
|
N/A | |
Completed |
NCT01490346 -
Tissue Drug Levels of HIV Medications
|
N/A | |
Completed |
NCT01076179 -
Kaletra in Combination With Antiretroviral Agents
|
N/A | |
Completed |
NCT01460433 -
Problems With Immune Recovery in the Gut Tissue
|
N/A | |
Completed |
NCT00317460 -
Buprenorphine and Integrated HIV Care
|
Phase 4 | |
Terminated |
NCT04240210 -
Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)
|
Phase 4 | |
Active, not recruiting |
NCT04704336 -
Integration of Hypertension Management Into HIV Care in Nigeria
|
N/A | |
Completed |
NCT03254277 -
3BNC117-LS First-in-Human Phase 1 Study
|
Phase 1 |